- Generic name
- Levetiracetam
- Strength
- 500 mg
- Dosage form
- Xr Tablet
- Manufactured by
- Advanced Chemical Industries PLC
Citazar 500 Xr Tablet
About Citazar 500 Xr Tablet
Citazar 500 is an extended-release tablet containing 500 mg of levetiracetam. It is an anti-epileptic medicine used to treat certain types of seizures in adults and adolescents, always as part of a plan set by a doctor.
There are 34 brands of Levetiracetam listed in Bangladesh. The lowest listed price is Citazar 250 mg Tablet at ৳ 15.11 per unit.
What is Citazar 500 Xr Tablet?
Citazar 500 XR Tablet is made by Advanced Chemical Industries PLC and contains levetiracetam, which belongs to a group of medicines called adjunct anti-epileptic drugs. It is prescribed for partial-onset seizures, which are a type of epilepsy seizure that starts in one part of the brain. Depending on the person, it may be used alone or alongside other epilepsy medicines. The 500 mg strength and the extended-release form mean each tablet contains 500 mg of levetiracetam and is designed to release the medicine over a longer period. How it is taken, and how often, is decided by the doctor. Anyone using it should follow the doctor's instructions and keep regular appointments.
Uses of Citazar 500
Citazar 500 is used to treat partial-onset seizures, a kind of epilepsy seizure that begins in one area of the brain, with or without spreading to the whole brain. In some people it is used together with other anti-epileptic medicines; in others it may be used alone, depending on the doctor's assessment. It is prescribed for adults and adolescents, and the doctor decides whether it suits a particular person. It is not a general treatment for all seizure types, so ask the doctor what it is being prescribed for and how it fits into the overall epilepsy plan.
How to use Citazar 500
Take Citazar 500 exactly as the doctor tells you. The tablet is an extended-release form, so it is usually swallowed whole rather than crushed or chewed; confirm this with the pharmacist. The doctor decides the starting amount, how often to take it and how the amount is adjusted over time, so never change the schedule yourself. If you miss a dose, ask the doctor or pharmacist what to do rather than doubling up. Do not stop the medicine suddenly on your own, because the doctor needs to manage any change in treatment. Keep the tablets in a cool, dry place away from light.
Side effects of Citazar 500
Like all medicines, Citazar 500 can cause side effects, though not everyone gets them. In adults, the more commonly reported effects include sleepiness, tiredness or weakness, infection and dizziness. Children may experience tiredness, aggression, a blocked nose, reduced appetite and irritability. Some people may notice other effects. Tell the doctor or pharmacist if any side effect bothers you or does not settle, and seek medical help promptly for anything severe or unexpected. Do not adjust the amount you take to manage side effects without speaking to the doctor first.
Safety and precautions
Citazar 500 is not recommended during pregnancy, or in women who could become pregnant and are not using contraception, unless the doctor considers it clinically necessary. Levetiracetam passes into breast milk, so breastfeeding is not recommended; if treatment is needed while breastfeeding, the doctor will weigh the benefits and risks. Tell the doctor about kidney or liver problems, because the amount taken may need adjusting. Rarely, this medicine has been linked with kidney injury and with reduced blood cell counts, so report unusual tiredness, fever or bruising. Anyone with an allergy to levetiracetam or similar medicines should not take it. Always ask the doctor first about any concerns.
Frequently asked questions
Is Citazar 500 safe during pregnancy or breastfeeding?
It is not recommended during pregnancy, or in women who could become pregnant without contraception, unless the doctor decides it is clinically necessary. It passes into breast milk, so breastfeeding is not recommended. If treatment is needed while breastfeeding, the doctor will weigh the benefits and risks. Discuss any plans for pregnancy with your doctor first.
What is Citazar 500 used for and what kind of medicine is it?
It is an anti-epileptic medicine containing levetiracetam, used to treat partial-onset seizures. It may be used alongside other epilepsy medicines or, in some cases, on its own, depending on the doctor's assessment. Ask your doctor what it is prescribed for in your situation and how it fits your overall treatment.
What do the dosage form and strength mean?
Citazar 500 is an extended-release tablet, meaning the tablet is designed to release the medicine gradually over a longer period rather than all at once. The 500 mg strength means each tablet contains 500 mg of levetiracetam. The doctor decides how the tablet is taken, how often, and how the amount is adjusted over time.
Can I stop Citazar 500 on my own if I feel better?
Do not stop or change the medicine on your own, even if you feel better. Stopping suddenly or altering the schedule can affect seizure control. The doctor decides how the medicine is started, adjusted or stopped. If you miss a dose or want to discuss your treatment, speak to your doctor or pharmacist first.
Indications
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy. ... Read more
- in the treatment of partial-onset seizures with or without secondary generalization in adults, adolescents, children and infants from 1 month of age with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
Dosage & Administration
Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more: The initial therapeutic dose is 500 mg twice daily. This dose can be started on the first day of treatment. Depending upon the clinical response and tolerability, the daily dose can be increased up to 1,500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decrease every two to four weeks.
Pediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Oral solution is the preferred formulation for use in this population. In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. In all of the above cases, oral solution should be used.
- Monotherapy: The safety and efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.
- Add-on therapy: Oral solution is the preferred formulation for use in infants and children under the age of 6 years. For children 6 years and above, oral solution should be used for doses under 250 mg, for doses not in multiples of 250 mg when dosing recommendation is not achievable by taking multiple tablets and for patients unable to swallow tablets. The lowest effective dose should be used. The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. Dosing for children 50 kg or greater is the same as in adults.
- Add-on therapy: For infants aged from 1 month to less than 6 months: The oral solution is the formulation to use in infants.
Interaction
Probenecid: Probenecid (500 mg four times daily), a renal tubular secretion blocking agent, has been shown to inhibit the renal clearance of the primary metabolite but not of levetiracetam. Nevertheless, the concentration of this metabolite remains low.
Methotrexate: Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.
Laxatives: There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.
Food and alcohol: The extent of absorption of levetiracetam was not altered by food, but the rate of absorption was slightly reduced. No data on the interaction of levetiracetam with alcohol are available.
Contraindications
Side Effects
- Adult patients: somnolence, asthenia, infection and dizziness
- Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Pregnancy & Lactation
Precautions & Warnings
Acute kidney injury: The use of levetiracetam has been very rarely associated with acute kidney injury with a time to onset ranging from a few days to several months.
Blood cell counts: Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing important weakness, pyrexia, recurrent infections or coagulation disorders.
Suicide: Suicide, suicide attempt, suicidal ideation and behaviour have been reported in patients treated with anti-epileptic agents (including levetiracetam). A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. The mechanism of this risk is not known. Therefore patients should be monitored for signs of depression and/or suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of depression and/or suicidal ideation or behaviour emerge.
Paediatric population: The tablet formulation is not adapted for use in infants and children under the age of 6 years. Available data in children did not suggest an impact on growth and puberty. However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown.
Overdose Effects
Storage Conditions
Alternative brands of Levetiracetam
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.